ClinicalTrials.gg
RecruitingNCT07141862PREFERPUBERUpdated Sep 3, 2025

Fertility Preservation in Children With Solid Tumors: Detection of Residual Disease by a Sensitive Method

An observational study in Neuroblastoma and Ewing Sarcoma, sponsored by University Hospital, Clermont-Ferrand. Recruiting at 1 site in France. Open to participants aged 2 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-09-03.

Sponsored by University Hospital, Clermont-Ferrand · Observational

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
89
Ages
2 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Neuroblastoma with a site in France — 10 open to participants now, 15 under way, 2 of them phase 3. Neuroblastoma · France.

Started
2025
with 1 other
Observational
4 of 54
3 open now
Primary completion
2027-06
later than 7 of 14 live
Registered
53rd of 54
by date

Among the 54 studies in Neuroblastoma with a site in France, this one is one of 2 that started in 2025, is one of 4 observational ones, reaches primary completion later than 7 of the 14 other live ones, and was the 53rd registered.

Neuroblastoma

676 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.

Browse Neuroblastoma studies →

Open to participants now

10 of the 54 studies in Neuroblastoma with a site in France are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 104 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 74 (71%) stop at 75 or younger; 101 take children under 18; 3 take healthy volunteers.

This study: 2 Years to 45 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Neuroblastoma with a site in France, or all of them as a file.
02

Study summary

In prepubertal patients, cryopreservation of ovarian or testicular tissue is currently the only available method for fertility preservation prior to gonadotoxic cancer treatments. However, this approach carries the risk of reintroducing malignant cells upon autotransplantation, particularly in cases of metastatic cancers such as neuroblastoma and Ewing sarcoma. Therefore, it is crucial to employ highly sensitive techniques to detect minimal residual disease (MRD) in preserved gonadal tissues.

This study aims to identify the most effective detection method by comparing the sensitivity and specificity of reverse transcription quantitative PCR (RT-qPCR) and droplet digital PCR (ddPCR) in identifying MRD of neuroblastoma and Ewing sarcoma in ovarian and testicular tissues from patients treated for these malignancies during infancy.

Read the detailed description

Ovarian and testicular cryopreservation is the only option to preserve the fertility of children diagnosed with cancer. Cancer treatments such as chemotherapy and radiotherapy can lead to gonadal toxicity. However, there is a risk of reintroducing tumor cells when the germinal tissue is reused. This is known as residual disease. This risk is higher in the case of metastatic cancers such as neuroblastoma and Ewing sarcoma. These two solid tumors are associated with a high risk of relapse and disease progression after treatment. Neuroblastoma is the most common extracranial solid tumor in children. One characteristic of this neuroendocrine tumor is its high frequency of metastatic disease. Several cases of metastasis have been reported in ovarian and testicular tissues.

Regarding Ewing sarcoma, it is the second most common bone cancer in children. Approximately 27% of patients show evidence of metastasis at diagnosis; these circulating tumor cells can reach the germinal tissues.

Several detection methods are available for these two solid tumors, such as histopathological analysis with hematoxylin-eosin staining, and immunohistochemistry targeting cellular markers with fluorescent antibodies. However, the main limitation of these two methods is their low sensitivity for detecting only a few tumor cells. That is why RT-qPCR and ddPCR, which have high detection sensitivity, have been developed. These two molecular methods are currently used for the detection of residual disease in leukemia and lymphoma. However, no studies have investigated the detection of residual disease of neuroblastoma and Ewing sarcoma by ddPCR in ovarian and testicular tissues.

Therefore, the goal of this study is to validate the detection of residual disease of neuroblastoma and Ewing sarcoma by ddPCR in ovarian and testicular tissues. In addition, the second goal is to evaluate the specificity and sensitivity of residual disease detection for these two solid tumors in ovarian and testicular tissues using RT-qPCR and ddPCR.

First, an in vitro model has been developed to mimic the metastatic dissemination of neuroblastoma and Ewing sarcoma in germinal tissues. To do this, two tumor cell lines will be used: IMR-32 for neuroblastoma and RD-ES for Ewing sarcoma. Then, 10 ovarian tissues and 10 testicular tissues will be contaminated with increasing quantities of neuroblastoma tumor cells: 5, 10, 20, and 100 tumor cells. The same procedure will be applied in the case of Ewing sarcoma. Ovarian tissues are derived from women of any age diagnosed with a benign cyst requiring laparoscopy. Testicular tissues are derived from men of any age diagnosed with non-obstructive azoospermia. These ovarian and testicular models have been validated by our team through preliminary work. These models are as close as possible to prepubertal tissues with immature gametes. Next, the investigators will perform RNA extraction with TRIzol reagent, followed by reverse transcription to generate complementary DNA (cDNA) and RT-qPCR and ddPCR to detect the specific tumor genes: PHOX2B for neuroblastoma and EWSR1-FLI1 for Ewing sarcoma.

Residual disease detection will be conducted on ovarian and testicular tissues collected from prepubertal patients diagnosed and treated for neuroblastoma or Ewing sarcoma during infancy. These patients underwent germinal tissue cryopreservation as a fertility preservation strategy following their cancer diagnosis.

Total RNA will be extracted from the cryopreserved tissues using TRIzol reagent. Subsequently, reverse transcription will be performed. The presence or absence of tumor-specific transcripts will be assessed using both reverse transcription quantitative PCR (RT-qPCR) and droplet digital PCR (ddPCR). Specifically, the neuroblastoma-associated PHOX2B gene and the Ewing sarcoma-specific EWSR1-FLI1 fusion transcript will be targeted.

By comparing the sensitivity and specificity of RT-qPCR and ddPCR for detecting minimal residual disease in these tissues, this study aims to determine the most effective and reliable protocol for identifying residual tumor cells. The findings will support the safe future use of cryopreserved ovarian and testicular tissues in fertility restoration for pediatric cancer survivors.

03

Conditions studied

  • Neuroblastoma
  • Ewing Sarcoma
04

Who can participate

Ages eligible
2 Years to 45 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Residual disease detection will be conducted on ovarian and testicular tissues collected from prepubertal patients diagnosed and treated for neuroblastoma or Ewing sarcoma during infancy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women of any age diagnosed with a benign cyst requiring laparoscopy may be included.
  • Men of any age diagnosed with a non-obstructive azoospermia may be included.
  • Prepubertal girls and boys diagnosed with neuroblastoma or Ewing sarcoma during infancy may be included.
  • Capable of providing written to participate in the research study
  • Affiliated with a social welfare service.
  • For prepubertal patients, written informed consent to participate in the research study must be provided by their parents or legal guardians.

Exclusion criteria

Exclusion Criteria:

  • None
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
89 participants (estimated)
Patient registry
No

Groups and cohorts

  • Detection of MRD of neuroblastoma and Ewing sarcoma in ovarian and testicular tissues using RT-qPCR

    First, the detection of minimal residual disease of neuroblastoma and Ewing sarcoma will be performed on an in vitro model that mimics the metastatic dissemination of these two solid tumors. Ovarian and testicular tissues will be contaminated with increasing quantities of tumor cells (0, 5, 10, 20, and 100 tumor cells) from neuroblastoma (IMR-32) and Ewing sarcoma (RD-ES). Then, the detection of MRD will be carried out on ovarian and testicular tissues from prepubertal patients diagnosed and treated for neuroblastoma and Ewing sarcoma during infancy. To detect this MRD in both models, the investigators will perform RNA extraction using TRIzol reagent, followed by reverse transcription and RT-qPCR to detect the specific tumor genes: PHOX2B for neuroblastoma and EWSR1-FLI1 for Ewing sarcoma.

    Diagnostic Test: RT-qPCR

  • Detection of MRD of neuroblastoma and Ewing sarcoma in ovarian and testicular tissues using ddPCR.

    First, the detection of MRD of neuroblastoma and Ewing sarcoma will be performed on an in vitro model that mimics the metastatic dissemination of these two solid tumors. Ovarian and testicular tissues will be contaminated with increasing quantities of tumor cells (0, 5, 10, 20, and 100 tumor cells) from neuroblastoma (IMR-32) and Ewing sarcoma (RD-ES). Then, the detection of MRD will be carried out on ovarian and testicular tissues from prepubertal patients diagnosed and treated for neuroblastoma and Ewing sarcoma during infancy. To detect this MRD in both models, the investigators will perform RNA extraction using TRIzol reagent, followed by reverse transcription and ddPCR to detect the specific tumor genes: PHOX2B for neuroblastoma and EWSR1-FLI1 for Ewing sarcoma.

    Diagnostic Test: ddPCR

Interventions

  • Diagnostic testRT-qPCR

    Detection of MRD of neuroblastoma and Ewing sarcoma in ovarian and testicular tissues using RT-qPCR

  • Diagnostic testddPCR

    Detection of MRD of neuroblastoma and Ewing sarcoma in ovarian and testicular tissues using ddPCR

06

What researchers measure

Primary outcomes

  1. Validation of residual disease detection of neuroblastoma and Ewing sarcoma by ddPCR in ovarian and testicular tissues.

    Detection of the copy number of specific tumor genes: PHOX2B for neuroblastoma and EWSR1-FLI1 for Ewing sarcoma in ovarian and testicular tissues using ddPCR. Residual disease will be detected in ovarian and testicular tissues contaminated with increasing quantities of tumor cells (0, 5, 10, 20, and 100 tumor cells) from neuroblastoma (IMR-32) and Ewing sarcoma (RD-ES), as well as in ovarian and testicular tissues from prepubertal patients diagnosed and treated for neuroblastoma and Ewing sarcoma during infancy.

    Time frame: From 02-2025 to 02-2026 for analysis of neuroblastoma; from 02-2026 to 12-2027 for analysis of Ewing sarcoma.

Secondary outcomes

  1. Evaluation of the specificity and sensitivity of RT-qPCR and ddPCR for detecting residual disease of neuroblastoma and Ewing sarcoma in ovarian and testicular tissues.

    Detection of the copy number of specific tumor genes: PHOX2B for neuroblastoma and EWSR1-FLI1 for Ewing sarcoma in ovarian and testicular tissues using RT-qPCR and ddPCR. Residual disease will be detected in ovarian and testicular tissues contaminated with increasing quantities of tumor cells (0, 5, 10, 20, and 100 tumor cells) from neuroblastoma (IMR-32) and Ewing sarcoma (RD-ES), as well as in ovarian and testicular tissues from prepubertal patients diagnosed and treated for neuroblastoma and Ewing sarcoma during infancy. The sensitivity and specificity of each detection method will then be compared.

    Time frame: From 02-2025 to 02-2026 for analysis of neuroblastoma; from 02-2026 to 12-2027 for analysis of Ewing sarcoma.

  2. Evaluation of the impact of ovarian tissue freezing protocols on RNA Quantity and Purity

    Two ovarian tissue freezing protocols will be tested. Half of the ovarian tissues contaminated by neuroblastoma tumor cells (IMR-32) will be frozen and thawed using the protocol describe by Gosden in 1994, and the other half using the protocol developed by Schubert in 2005. RNA quantity and purity, including protein and chemical contamination will be compared between the two protocols. The same analysis will be performed on ovarian tissues contaminated with Ewing sarcoma tumor cells (RD-ES).

    Time frame: From 02-2025 to 02-2026 for analysis of neuroblastoma; from 02-2026 to 12-2027 for analysis of Ewing sarcoma

07

Study locations

1 of 1 sites recruiting
  • University hospital
    Clermont-Ferrand, Auvergne 63000, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jun 2027, 28 months after the start.

Of 34 observational studies under Neuroblastoma, half reached primary completion within 213 months of starting (the median), counting those still running; a quarter within 74 and three quarters within 304. This study's planned 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2025
First posted
Aug 26, 2025
StartActual
Feb 1, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Sep 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07141862
Responsible party
Sponsor
First posted
Aug 26, 2025
Start date
Feb 1, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 3, 2025

Study contacts

Lise Laclautre
Contact
drci@chu-clermontferrand.fr
04 73 75 11 95
Florence BRUGNON, MD, PhD, HDR
principal investigator · University Hospital, Clermont-Ferrand

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion